Healthcare
Live Price
Offline$13.34
+1.44% today
1Y Change
+37.68%
Window
Jun 27, 2025 → Jun 17, 2026
Coverage: 245 bars · Jun 27, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Astellas Pharma Inc. (ALPMY) is a Healthcare stock with a market cap of $3.95T. The stock last traded around $13.34 and up 37.7% across the available one-year price window (Jun 27, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +18.6%, EPS growth of +508.7%, a dividend yield of 3.5%. What stands out right now is revenue +18.6%, EPS +508.7%, free cash flow +293.1% with operating margin 18.9% and ROIC 12.1%. The dividend matters to the case here, with a current yield around 3.5%. Valuation is more restrained than many high-expectation growth names at P/E 13.6 and price/sales 1.8. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines ALPMY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ALPMY
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ALPMY Max Drawdown
-21.28%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ALPMY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.2T
-3.6% YoY
FY Net Income
$120.6B
-2.8% YoY
Free Cash Flow
$230.4B
+26.8% YoY
Revenue Growth
+18.6%
EPS Growth
+508.7%
Gross Margin
76.1%
Net Margin
13.6%
Income statement
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1912.3B | 1603.7B | 1518.6B | 1296.2B | 1249.5B |
| Gross Profit | 1563.1B | 1311.2B | 1191.8B | 1014.9B | 979.7B |
| Operating Income | 41.0B | 25.5B | 285.4B | 155.7B | 136.1B |
| EBITDA | 248.0B | 194.8B | 246.9B | 241.5B | 220.3B |
| Net Income | 50.7B | 17.0B | 98.7B | 124.1B | 120.6B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
JPY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 188.4B | 335.7B | 376.8B | 316.0B | 326.1B |
| Total Assets | 3339.5B | 3569.6B | 2456.5B | 2332.4B | 2273.6B |
| Total Liabilities | 1826.3B | 1973.6B | 948.6B | 872.1B | 887.5B |
| Shareholder Equity | 1513.3B | 1596.0B | 1508.0B | 1460.3B | 1386.1B |
| Total Debt | 831.4B | 920.0B | 200.0B | 212.7B | 278.3B |
| Net Debt | 643.1B | 584.3B | -176.8B | -103.2B | -47.9B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
307.9B
+19.3% YoY
Capital Expenditures
77.4B
-1.3% YoY
Free Cash Flow
230.4B
+26.8% YoY
Key ratios
Gross Margin
76.1%
Operating Margin
18.9%
Net Margin
13.6%
ROE
17.4%
Debt / Equity
0.31x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.